1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Digestive tract conditions
  5. Inflammatory bowel disease

Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis

Evidence summary [ES35] Published: 24 February 2021

  • Advice
  • Tools and resources
  • Evidence

Tools and resources

Resource impact

  • Resource impact report PDF 194 KB 24 February 2021  
  • Resource impact template Excel 1.42 MB 24 February 2021